» Articles » PMID: 22713237

Combined Inhibition of Chk1 and Wee1: in Vitro Synergistic Effect Translates to Tumor Growth Inhibition in Vivo

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2012 Jun 21
PMID 22713237
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Targeting Chk1 protein kinase can enhance the antitumor effects of radio- and chemotherapy. Recent evidence disclosed a role of Chk1 in unperturbed cell proliferation and survival, implying that Chk1 inhibitors could also be effective as single agents in tumors with a specific genetic background. To identify genes in synthetic lethality with Chk1, we did a high-throughput screening using a siRNA library directed against 719 human protein kinases in the human ovarian cancer cell line OVCAR-5, resistant to Chk1 inhibitors. Wee1 tyrosine kinase was the most significant gene in synthetic lethality with Chk1. Treatment with non-toxic concentrations of a Chk1 inhibitor (PF-00477736) and a Wee1 inhibitor (MK-1775) confirmed the marked synergistic effect in various human cancer cell lines (breast, ovarian, colon, prostate), independently of the p53 status. Detailed molecular analysis showed that the combination caused cancer cells to undergo premature mitosis before the end of DNA replication, with damaged DNA leading to cell death partly by apoptosis. In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity. These data provide a strong rationale for the clinical investigation of the combination of a Chk1 and a Wee1 inhibitor.

Citing Articles

A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells.

Cera M, Bastianello G, Purushothaman D, Andronache A, Ascione F, Robusto M Sci Rep. 2024; 14(1):30786.

PMID: 39730498 PMC: 11680690. DOI: 10.1038/s41598-024-80837-w.


Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models.

Stewart A, Song J, Pickard L, Muggiolu G, Sauvaigo S, Brandon A BJC Rep. 2024; 2(1):27.

PMID: 39516567 PMC: 11523970. DOI: 10.1038/s44276-024-00048-8.


Targeting the DNA damage response in cancer.

Federica G, Michela C, Giovanna D MedComm (2020). 2024; 5(11):e788.

PMID: 39492835 PMC: 11527828. DOI: 10.1002/mco2.788.


Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.

Chao Y, Chen Y, Zheng W, Demanelis K, Liu Y, Connelly J Oncogene. 2024; 43(11):789-803.

PMID: 38273024 PMC: 11556418. DOI: 10.1038/s41388-024-02939-z.


An update of predictive biomarkers related to WEE1 inhibition in cancer therapy.

Wang Z, Li W, Li F, Xiao R J Cancer Res Clin Oncol. 2024; 150(1):13.

PMID: 38231277 PMC: 10794259. DOI: 10.1007/s00432-023-05527-y.